DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma (NCT04696029)

🧪 Interventions in This Study

• Difluoromethylornithine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

• Arkansas Children's Hospital — Little Rock, Arkansas
• UCSF Benioff Children's Hospital Oakland — Oakland, California
• UC Davis Comprehensive Cancer Center — Sacramento, California
• Rady Children's Hospital — San Diego, California
• Stanford University — Stanford, California
• Connecticut Children's Hospital — Hartford, Connecticut
• Nicklaus Children's Hospital — Miami, Florida
• Arnold Palmer Hospital for Children — Orlando, Florida
• All Children's Hospital Johns Hopkins Medicine — St. Petersburg, Florida
• St. Joseph's Children's Hospital — Tampa, Florida
• Kapiolani Medical Center for Women and Children — Honolulu, Hawaii
• Advocate Aurora Research Institute — Chicago, Illinois
• Kentucky Children's Hospital — Lexington, Kentucky
• Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine — Louisville, Kentucky
• Children's Mercy Hospitals and Clinics — Kansas City, Missouri
• Cardinal Glennon Children's Medical Center — St Louis, Missouri
• Hackensack University Medical Center — Hackensack, New Jersey
• Levine Children's Hospital — Charlotte, North Carolina
• Duke University — Durham, North Carolina
• University of Oklahoma — Oklahoma City, Oklahoma
• Randall Children's Hospital — Portland, Oregon
• Penn State Milton S. Hershey Medical Center and Children's Hospital — Hershey, Pennsylvania
• Hasbro Children's Hospital — Providence, Rhode Island
• Medical University of South Carolina — Charleston, South Carolina
• Dell Children's Blood and Cancer Center — Austin, Texas

📞 Contact the Study Coordinator

Phone: (717) 531-0003

Email: BCCEnroll@pennstatehealth.psu.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Medulloblastoma

• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma — Birmingham, Alabama
• A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma — Palo Alto, California
• A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma — Los Angeles, California
• HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors — Birmingham, Alabama
• Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma — Birmingham, Alabama
• Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease — San Francisco, California

Explore by condition: All Medulloblastoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.